ALNY Crosses Above Average Analyst Target
July 21, 2017 at 09:14 AM EDT
In recent trading, shares of Alnylam Pharmaceuticals Inc (ALNY) have crossed above the average analyst 12-month target price of $78.54, changing hands for $80.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..